155 related articles for article (PubMed ID: 16054578)
1. Pre-trial evaluation of the potential for unblinding in drug trials: a prototype example.
Walter SD; Awasthi S; Jeyaseelan L
Contemp Clin Trials; 2005 Aug; 26(4):459-68. PubMed ID: 16054578
[TBL] [Abstract][Full Text] [Related]
2. Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines.
Rees JR; Wade TJ; Levy DA; Colford JM; Hilton JF
Contemp Clin Trials; 2005 Feb; 26(1):25-37. PubMed ID: 15837450
[TBL] [Abstract][Full Text] [Related]
3. Is it possible to blind a trial for community-acquired pneumonia?
Boucher HW
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
[TBL] [Abstract][Full Text] [Related]
4. Assessment of blinding in clinical trials.
Bang H; Ni L; Davis CE
Control Clin Trials; 2004 Apr; 25(2):143-56. PubMed ID: 15020033
[TBL] [Abstract][Full Text] [Related]
5. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial.
Piaggio G; Elbourne D; Schulz KF; Villar J; Pinol AP; Gülmezoglu AM;
BMC Med Res Methodol; 2003 Oct; 3():19. PubMed ID: 14525622
[TBL] [Abstract][Full Text] [Related]
6. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.
Hróbjartsson A; Forfang E; Haahr MT; Als-Nielsen B; Brorson S
Int J Epidemiol; 2007 Jun; 36(3):654-63. PubMed ID: 17440024
[TBL] [Abstract][Full Text] [Related]
7. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
Licciardone JC; Russo DP
J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
[TBL] [Abstract][Full Text] [Related]
8. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
9. Placebo surgery research: a blinding imperative.
Heckerling PS
J Clin Epidemiol; 2006 Sep; 59(9):876-80. PubMed ID: 16895807
[TBL] [Abstract][Full Text] [Related]
10. A review of blinding in randomized controlled trials found results inconsistent and questionable.
Boutron I; Estellat C; Ravaud P
J Clin Epidemiol; 2005 Dec; 58(12):1220-6. PubMed ID: 16291465
[TBL] [Abstract][Full Text] [Related]
11. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
Haahr MT; Hróbjartsson A
Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
[TBL] [Abstract][Full Text] [Related]
12. Blinding strategies in the conduct and reporting of a randomized placebo-controlled device trial.
Houweling AH; Shapiro S; Cohen JM; Kahn SR
Clin Trials; 2014 Oct; 11(5):547-52. PubMed ID: 24902921
[TBL] [Abstract][Full Text] [Related]
13. Blinding in randomized clinical trials: imposed impartiality.
Hróbjartsson A; Boutron I
Clin Pharmacol Ther; 2011 Nov; 90(5):732-6. PubMed ID: 21993424
[TBL] [Abstract][Full Text] [Related]
14. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations].
Dorhout Mees EJ
Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2228. PubMed ID: 11103264
[No Abstract] [Full Text] [Related]
15. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials.
Boutron I; Tubach F; Giraudeau B; Ravaud P
J Clin Epidemiol; 2004 Jun; 57(6):543-50. PubMed ID: 15246122
[TBL] [Abstract][Full Text] [Related]
16. Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study.
Hsu VM; Khanna D; Smith E; Filemon T; Whelton S; Lopata M; Davis JC; Polito A; Heck L; Molitor J; Abeles M; Granda J; Korn J; Clements P;
Clin Trials; 2010 Feb; 7(1):85-9. PubMed ID: 20032002
[TBL] [Abstract][Full Text] [Related]
17. Redefining the randomized controlled trial in the context of acupuncture research.
Walji R; Boon H
Complement Ther Clin Pract; 2006 May; 12(2):91-6. PubMed ID: 16648085
[TBL] [Abstract][Full Text] [Related]
18. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
19. Rater bias in a blinded randomized placebo-controlled psychiatry trial.
Marcus SM; Gorman JM; Tu X; Gibbons RD; Barlow DH; Woods SW; Katharine Shear M
Stat Med; 2006 Aug; 25(16):2762-70. PubMed ID: 16345016
[TBL] [Abstract][Full Text] [Related]
20. On non-inferiority margin and statistical tests in active control trials.
Chow SC; Shao J
Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
